Creative Biolabs is dedicated to helping researchers overcome gene therapy delivery research challenges with its wide technical support and services.

Gene therapy is highly promising for the treatment of numerous genetic disorders, but there are significant restrictions on its application to effective clinical interventions. Most prominent among these is the development of efficient and safe systems of gene delivery, both viral and non-viral vectors.

Creative Biolabs has recently enhanced its technology platform to enable viral vector manufacturing from small to large scales with good titers, purity, potency, and consistency.

"Our researchers are highly skilled at constructing, developing, and cloning viral vectors such as adenoviral, lentiviral, and adeno-associated virus (AAV) vectors," the company director explained. "We aim to use our experience and technical expertise in viral vectors to enable researchers' research and speed up scientific advancements in this field."

On the contrary, viral vectors are complemented by non-viral vectors like lipid nanoparticles (LNPs), polymeric nanoparticles, and physical methods like electroporation with alternative modes for gene therapy delivery.

"Non-viral delivery systems like LNPs have proven to be a good alternative. LNPs can encapsulate nucleic acids, protecting them from degradation and allowing targeted delivery," said a Creative Biolabs researcher.

Having LNP formulations optimized as stable, biocompatible, and efficiently cell-targeting, however, requires sophisticated research and development.

Leaning on state-of-the-art facilities and technical expertise, Creative Biolabs offers specialized solutions to optimize vector systems, increase delivery efficiency, and optimize safety profiles.

In addition to technical support, Creative Biolabs also assists with the daunting regulatory landscape associated with gene therapy products, facilitating the transition from research through clinical trials.